Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Liquidia Technologies Receives $3 Million In Funding Through U.S. Commerce Departmentís National Institute Of Standards And Technology

Abstract:
Funding Will Enhance Liquidia's PRINTģ Manufacturing Process

Liquidia Technologies Receives $3 Million In Funding Through U.S. Commerce Departmentís National Institute Of Standards And Technology

Research Triangle Park, NC | Posted on December 18th, 2009

Liquidia Technologies today announced it will receive approximately $3 million in funding from the U.S. Commerce Department's National Institute of Standards and Technology (NIST) to further develop and scale‐up the company's PRINT manufacturing process. As part of its Technology Innovation Program (TIP), NIST announced it will fund new cost‐sharing projects to support innovative technologies that address critical national needs.

"We are very excited to have been selected by NIST as one of the 20 projects to receive funding through the TIP program," said Tom Templeman, Senior Vice President, Integrated Supply Chain at Liquidia. "This investment will support our continued development of PRINT manufacturing, which will allow us to develop clinically relevant quantities of particles for innovative vaccines and therapeutics."

The PRINT manufacturing process uses a proprietary roll‐to‐roll method that allows Liquidia to produce precisely engineered particles, which offer safer and more efficient delivery of vaccine and therapeutic drug products. The capabilities realized as a direct result of this project will support the advancement of a platform of products, including the company's initial vaccine product which is expected to enter clinical trials next year.

"As an industry, we are on the cusp of great therapeutic advancements in areas where unmet medical needs still persist," said Neal Fowler, CEO of Liquidia Technologies. "An investment such as this plays a critical role in enabling Liquidia to advance innovative products to the next stage of development where we will begin to see the true potential for patients."

####

About Liquidia Technologies
Liquidia Technologies is a privately‐held nanotechnology company that develops and manufactures precisely engineered particles for improved delivery of biological and small molecule therapeutics. The company is currently advancing products within the fields of vaccines, nucleic acid delivery, and inhaled therapeutics to address critical unmet needs in the treatment of human disease. The company was founded in 2004 and is located in Research Triangle Park, North Carolina.

For more information, please click here

Contacts:
Elle Pishny
919‐328‐4361

Copyright © Liquidia Technologies

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

ICN2 researchers compute unprecedented values for spin lifetime anisotropy in graphene November 17th, 2017

Math gets real in strong, lightweight structures: Rice University researchers use 3-D printers to turn century-old theory into complex schwarzites November 16th, 2017

The stacked color sensor: True colors meet minimization November 16th, 2017

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

Govt.-Legislation/Regulation/Funding/Policy

EC Project Aims at Creating and Commercializing Cyber-Physical-System Solutions November 14th, 2017

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3ís significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Leti Joins DARPA-Funded Project to Develop Implantable Device for Restoring Vision November 9th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Nanomedicine

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3ís significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

A new way to mix oil and water: Condensation-based method developed at MIT could create stable nanoscale emulsions November 8th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Announcements

ICN2 researchers compute unprecedented values for spin lifetime anisotropy in graphene November 17th, 2017

Math gets real in strong, lightweight structures: Rice University researchers use 3-D printers to turn century-old theory into complex schwarzites November 16th, 2017

The stacked color sensor: True colors meet minimization November 16th, 2017

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

Nanobiotechnology

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3ís significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Age-old malaria treatment found to improve nanoparticle delivery to tumors: Nanomedicine researchers find new use for 70-year-old drug November 7th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project